TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19249633
Drug: Prasugrel (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (60 mg loading, 10 mg maintenance)
Study: 19249633
Drug: Clopidogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300 mg loading, 75 mg maintenance)
Study: 9512875
Drug: Amiloride hydrochlorothiazide
Normalized name: amiloride / hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride hydrochlorothiazide (5/50 mg/d)
Study: 1826912
Drug: Atenolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (100 mg/d)
Study: 9512875
Drug: Nifedipine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (40 mg/d)
Study: 18326980
Drug: Perindopril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (4 mg/d)
Study: 29718967
Drug: Bedaquiline 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedaquiline 400 mg alone
Study: 29718967
Drug: Bedaquiline 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedaquiline 400 mg plus Rifampin 600 mg
Study: 29718967
Drug: Bedaquiline 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedaquiline 400 mg plus Rifabutin 300 mg
Study: 27236272
Drug: AKB‐9778 monotherapy:
Approvals — FDA: no, EMA: no, PMDA: no
Description: AKB‐9778 monotherapy: subcutaneous AKB‐9778 15 mg BID + monthly sham intraocular injections
Study: 27236272
Drug: Combination therapy:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy: subcutaneous AKB‐9778 15 mg BID + monthly 0.3 mg ranibizumab
Study: 27236272
Drug: Ranibizumab monotherapy:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab monotherapy: subcutaneous placebo injections BID + monthly 0.3 mg ranibizumab
Study: 24120712
Drug: Oseltamivir (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir (75 mg b.i.d. for 5 days)
Study: 21775146
Drug: Pregabalin 150
Normalized name: pregabalin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 150 mg/day for the first 3 days, then 300 mg/day for a further 2 days
Study: 16546843
Drug: Doxazosin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (4 mg/day for 2 weeks)
Study: 9878015
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination drug therapy with indinavir, zidovudine, and lamivudine
Study: 9878015
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination drug therapy after either indinavir or zidovudine-lamivudine treatment
Study: 9878015
Drug: Prolonged indinavir-zidovudine-lamivudine
Normalized name: lamivudine / zidovudine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged indinavir-zidovudine-lamivudine treatment
Study: 8529495
Drug: Pre-filled insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-filled insulin pen (NovoLet)
Study: 6759062
Drug: Ciramadol 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciramadol 40 mg
Study: 17470024
Drug: 0.2% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% chlorhexidine spray
Study: 30920975
Drug: Silymarin 140
Normalized name: silymarin 140 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin 140 mg/day
Study: 27659294
Drug: Erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 150 mg/day until disease progression or unacceptable toxicity
Study: 25662553
Drug: Bioadhesive chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioadhesive chlorhexidine gel 0.2%
Study: 21946712
Drug: ZeroFly® insecticide
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZeroFly® insecticide incorporated plastic sheeting (deltamethrin 2.0 g/kg or 265 mg/m2)
Study: 16754759
Drug: Team Solutions
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Team Solutions intervention (24-week psychoeducational group focused on illness management)
Study: 11822998
Drug: Propranolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40 mg four times daily for 10 days)
Study: 9661546
Drug: Dexamethasone 1
Normalized name: dexamethasone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 1 mg/kg (maximal dose 25 mg)
Study: 7631610
Drug: Noninvasive technique
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noninvasive technique after phenylephrine injection
Study: 7631610
Drug: Invasive technique
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invasive technique after phenylephrine injection
Study: 320832
Drug: Coated, rapidly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coated, rapidly dissolving lithium carbonate tablets
Study: 320832
Drug: Medium-slow-release lithium
Normalized name: Slow-Fe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-slow-release lithium sulphate tablets
Study: 320832
Drug: Slow-release lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release lithium sulphate tablets
Study: 6182175
Drug: mianserin 10
Normalized name: mianserin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: mianserin 10 mg 3 times daily for 1 week followed by 60 mg mianserin daily for a second week
Study: 6182175
Drug: amitriptyline 25
Normalized name: amitriptyline 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: amitriptyline 25 mg 3 times daily for 1 week followed by 150 mg amitriptyline daily for a second week
Study: 6182175
Drug: placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo treatment for 14 days
Study: 26555871
Drug: Tizanidine 4
Normalized name: tizanidine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tizanidine 4 mg orally 1 hour before surgery and twice daily during the first postoperative week
Study: 24826894
Drug: Prophylactic platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic platelet transfusion policy (counts <10 × 10(9) /L)
Study: 22842177
Drug: 1 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg/day Fungisome
Study: 22842177
Drug: 3 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg/day Fungisome
Study: 22842177
Drug: 1 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg/day conventional amphotericin B
Study: 17650789
Drug: Yiguan Decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yiguan Decoction (YGD) plus NP protocol of chemotherapy
Study: 17650789
Drug: NP protocol
Normalized name: NP Thyroid Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: NP protocol of chemotherapy
Study: 11844942
Drug: Comprehensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive treatment programme with hypnosis
Study: 11844942
Drug: Comprehensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive treatment programme without hypnosis
Study: 7444376
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of calciumacetylsalicylic acid
Study: 7444376
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of calciumacetylsalicylic acid
Study: 7444376
Drug: Repeated doses
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated doses of 100 mg of calciumacetylsalicylic acid at 12 h intervals
Study: 7444376
Drug: 12 h
Normalized name: 12 Hour Cold
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 h 100 mg doses of calciumacetylsalicylic acid (equal to 80 mg of aspirin)
Study: 27828791
Drug: Vernakalant (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vernakalant (3 mg/kg infusion for 10 minutes, followed by 2 mg/kg infusion for 15 minutes if needed)
Study: 27828791
Drug: Placebo (infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (infusion for 10 minutes, followed by placebo infusion for 15 minutes if needed)
Study: 20624152
Drug: Supplementation with
Normalized name: Similac For Supplementation with Iron Powder for Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplementation with docosahexaenoic acid (DHA) and arachidonic acid (AA) - 0.5 mL oil (32 mg DHA and 31 mg AA) per 100 mL milk from 1 week after birth until discharge (9 weeks on average)
Study: 19494788
Drug: Erlotinib 1400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 1400 mg weekly on days 2, 9, and 16 plus Pemetrexed 500 mg/m every 21 days (arm A)
Study: 19494788
Drug: Erlotinib 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 250 mg on days 2 to 16 plus Pemetrexed 500 mg/m every 21 days (arm B)
Study: 14742841
Drug: Calcium (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1.2 g/d) and vitamin D (8 microg/d) supplementation for 6 months in RYGB women with low bone mass, n = 13
Study: 2446081
Drug: Ketanserin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (40 mg orally)
Study: 2446081
Drug: Ritanserin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritanserin (10 mg orally)
Study: 2446081
Drug: Ritanserin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritanserin (20 mg orally)
Study: 23605170
Drug: Metformin (1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1,500 mg) and folic acid (1 mg) per day for 2 months
Study: 23605170
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (1 mg) per day for 2 months (Control)
Study: 19620848
Drug: IPX054 (50/200
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPX054 (50/200 mg) twice daily
Study: 19620848
Drug: CD/LD (25/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD/LD (25/100 mg) 4 times daily
Study: 12612511
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg midazolam plus 50 mg meperidine (Group B)
Study: 12612511
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg midazolam and placebo (Group A)
Study: 8811136
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium (Voltaren), 50 mg two or three times a day
Study: 1329231
Drug: Teniposide administration
Normalized name: Teniposide
DrugBank: Teniposide (DB00444)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Teniposide administration (schedule not specified)
Study: 6724125
Drug: Carbamazepine (CBZ)
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine (CBZ) 200 mg tablets
Study: 6724125
Drug: Carbamazepine (CBZ)
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine (CBZ) 400 mg tablets
Study: 29618121
Drug: Strategic bDMARDs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strategic bDMARDs treatment (ustekinumab, secukinumab, TNF inhibitors based on T cell phenotype)
Study: 29618121
Drug: Standard bDMARDs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard bDMARDs treatment
Study: 29521922
Drug: Foot exercises
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foot exercises (daily for 12 weeks)
Study: 23726668
Drug: Citalopram treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram treatment for 12 weeks
Study: 18766387
Drug: beta‐TCP (Cerasorb)
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta‐TCP (Cerasorb) in combination with PRP
Study: 16739362
Drug: Iberogast (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iberogast (3 x 20 drops daily for 4 weeks)
Study: 11321874
Drug: G-CSF or
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF or GM-CSF
Study: 3444905
Drug: lonidamine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: lonidamine (150 mg t.i.d.) + radiotherapy (RT)
Study: 9016421
Drug: L-thyroxine replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-thyroxine replacement therapy
Study: 16580290
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 (2 mg)
Study: 12680890
Drug: Ibuprofen 600
Normalized name: ibuprofen 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 600 mg x 4 for 3 days
Study: 12680890
Drug: Paracetamol 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 1000 mg x 4 for 3 days
Study: 30158057
Drug: Increased dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased dose of loop diuretics
Study: 30158057
Drug: Continuous use
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous use of loop diuretics
Study: 30158057
Drug: Initiation or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initiation or discontinuation of diuretics
Study: 27647847
Drug: Renal artery
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renal artery stenting plus optimal medical therapy
Study: 23706520
Drug: Spironolactone 25
Normalized name: spironolactone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 25 mg daily for 20 weeks
Study: 8305642
Drug: GFR measurements
Approvals — FDA: no, EMA: no, PMDA: no
Description: GFR measurements using renal clearance of [125I]iothalamate after an sc injection without epinephrine.
Study: 2863920
Drug: Alprazolam (AZ)
Normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alprazolam (AZ) 0.25 mg
Study: 2863920
Drug: Diazepam (DZ)
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diazepam (DZ) 5 mg
Study: 2863920
Drug: Alprazolam (AZ)
Normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alprazolam (AZ) 0.75 mg
Study: 24802974
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg oral Δ(9) -tetrahydrocannabinol (THC)
Study: 20689095
Drug: Pro-CHO (3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pro-CHO (3.6 kcal/kg, 0.36 g protein/kg)
Study: 18573825
Drug: Interferon beta
Normalized name: Interferon beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon beta therapy
Study: 12809076
Drug: Testosterone treatment
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone treatment (200 mg intramuscularly every 2 weeks)
Study: 8758538
Drug: Alpha Interferon
Normalized name: Natural alpha interferon
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha Interferon therapy
Study: 8758538
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus natural alpha Interferon
Study: 8758538
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose dexamethasone‐alpha Interferon
Study: 29980851
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein concentrate (0.33 g·kg BM‐1)
Study: 29980851
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein concentrate (0.33 g·kg BM‐1) with prior aerobic exercise
Study: 29980851
Drug: Control (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (75 g oral glucose tolerance test)
Study: 20443797
Drug: Conical neck
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conical neck design implant (C)
Study: 20443797
Drug: Straight shape
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Straight shape implant (S)
Study: 12352800
Drug: CRM(197) pneumococcal
Normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRM(197) pneumococcal conjugate vaccine (PCV)
Study: 12352800
Drug: Meningococcal type
Normalized name: MENINGOCOCCAL B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal type C CRM(197) conjugate vaccine
Study: 7754005
Drug: Transcatheter arterial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcatheter arterial embolization (TAE) with gelatin sponge (GS) containing anticancer agents (protocol 1)
Study: 7754005
Drug: Transcatheter arterial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcatheter arterial embolization (TAE) with GS and iodized oil mixed with anticancer agents (protocol 2)
Study: 7754005
Drug: Transcatheter arterial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcatheter arterial embolization (TAE) with iodized oil with anticancer agents (protocol 3)
Study: 2186321
Drug: CHOEP (cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHOEP (cyclophosphamide 750 mg/m2 i.v. day 1, doxorubicin 50 mg/m2 i.v. day 1, vincristine 2 mg i.v. day 1, etoposide 100 mg/m2 i.v. days 3-5, prednisolone 100 mg p.o. days 1-5)
Study: 2186321
Drug: hCHOP alternating
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCHOP alternating with IVEP (cyclophosphamide 1,200 mg/m2 i.v. day 1, doxorubicin 40 mg/m2 i.v. days 1 + 2, vincristine 2 mg i.v. day 1, prednisolone 100 mg p.o. days 1-5)
Study: 31153358
Drug: Scalp nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scalp nerve block (SNB) with 15 mL of 0.75% ropivacaine
Study: 31153358
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic infiltration (LA) with 15 mL of 0.75% ropivacaine
Study: 31153358
Drug: Routine intravenous
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine intravenous analgesia (Control group)
Study: 28636855
Drug: RIV4 (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIV4 (45 μg of recombinant hemagglutinin [HA] per strain, 180 μg of protein per dose)
Study: 28636855
Drug: IIV4 (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: IIV4 (15 μg of HA per strain, 60 μg of protein per dose)
Study: 20627917
Drug: Automatic positive
Normalized name: AMMONIA,AROMATIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automatic positive airway pressure (APAP) titration
Study: 24163991
Drug: Polysomnography manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polysomnography manual titration
Study: 8156653
Drug: Metoclopramide 20
Normalized name: metoclopramide 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 20 mg (0.2-0.3 mg/kg)
Study: 8156653
Drug: Prochlorperazine 12.5
Normalized name: prochlorperazine 12.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prochlorperazine 12.5 mg (0.1-0.2 mg/kg)
Study: 3131791
Drug: Alcohol (0.695
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.695 g/kg)
Study: 31690107
Drug: 3 months
Normalized name: TABLET, DOSE PACK, 3 MONTHS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 months of directly observed once-weekly rifapentine plus isoniazid
Study: 31690107
Drug: 9 months
Normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 9 months of self-administered daily isoniazid
Study: 23231878
Drug: Culturally adapted
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally adapted cognitive behavioural therapy for psychosis (CaCBTp)
Study: 21209123
Drug: ADA160/80 (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADA160/80 (160 mg at week 0, 80 mg at week 2, 40 mg at weeks 4 and 6)
Study: 21209123
Drug: ADA80/40 (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADA80/40 (80 mg at week 0, 40 mg at weeks 2, 4 and 6)
Study: 17033926
Drug: CMF chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF chemotherapy plus tamoxifen for 1 year
Study: 17033926
Drug: CMF chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF chemotherapy for 1 year
Study: 9573748
Drug: Estrogens alone
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogens alone administered transdermically (17 beta‐estradiol, 50 micrograms/day)
Study: 9573748
Drug: Transdermic estrogens
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermic estrogens plus oral progestagen (17 beta‐estradiol 50 micrograms/day, acetate medroxyprogestogen 10 mg/day for 12 days per month)
Study: 9573748
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine estrogens (0.625 mg/day) plus oral progestagen (10 mg/day for 12 days per month)
Study: 20470802
Drug: Anti-TNF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNF treatment plus DMARDs
Study: 15821690
Drug: Functional appliances
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional appliances (Fränkel II or Herbst); average treatment duration to final cephalograms: 35.8 months
Study: 15821690
Drug: Bilateral sagittal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral sagittal split ramus osteotomy; average treatment duration to final cephalograms: 34.9 months
Study: 12388961
Drug: Dinoprostone gel
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dinoprostone gel 5 mg intracervically, with repeated dosing one time 6 hours later
Study: 7588670
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium 100 mg suppositories
Study: 2105670
Drug: Glycerol-based peripheral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerol-based peripheral hyperalimentation solution (after eliminating in-line filters)
Study: 477550
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of theophylline, diprophylline, and proxyphylline
Study: 31870451
Drug: Physiotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapy with protein-rich nutritional supplement plus anabolic steroid
Study: 31870451
Drug: Physiotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapy with protein-rich nutritional supplement plus placebo
Study: 28291238
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg escitalopram (ESC)
Study: 2682593
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg amitriptyline (AMI)